NCT07530796
Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)
At risk: Primary completion moved 2 years 2 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 1, 2029 to Jul 1, 2031 Show 8 more changesShow less
- Primary endpoint(s) modified
- Enrolling by invitation only
- Start date: May 1, 2026 to Nov 1, 2026
- Eligibility criteria expanded, about 11 words
- Study completion pushed from May 1, 2032 to Jul 1, 2032
- Study sites: 0 to 1
- Interventions: scAAV9/AGA (Genetic) to scAAV9/AGA (Genetic)
- Secondary endpoints: 2 to 3
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence, severity, and causality of a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)
Timeframe: Through Day 720
Secondary (2)
Biologic activity following a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)
Preliminary efficacy following a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)
Arms and interventions
DANAGALEX (scAAV9/AGA) Gene TherapyExperimental
Cohort 1: adults aged 18-45 years; Cohort 2: adolescents aged 12-17 years; Cohort 3: children aged 4-11 years. All participants receive a single dose of DANAGALEX (scAAV9/AGA). Progression to younger cohorts is subject to protocol-defined safety observation and DSMB review.
Genetic: scAAV9/AGA
Sites
1 site in 1 country
- Louisiana State University Health Sciences CenterShreveport, Louisiana, United States